

STATISTICAL COMPENDIUM: MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2005 UNITED STATES

LIST OF TABLES

OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

FOR ALL MEDICAID BENEFICIARIES

- TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY
- TABLE 3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE 5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH. BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

FOR ALL NONDUAL BENEFICIARIES

- TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES. BY BASIS OF ELIGIBILITY
- TABLE ND.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY. BY BENEFICIARY CHARACTERISTIC
- TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE ND.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND
- **BENEFICIARY CHARACTERISTIC**
- TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT. BY TOP 10 DRUG GROUP
- TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC
- TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND
- THERAPEUTIC CATEGORY
- TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,
- BY TOP 10 DRUG GROUP
- TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY
- BENEFICIARY CHARACTERISTIC
- TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH,
- BY BENEFICIARY CHARACTERISTIC
- TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES
- AMONG NONDUALS

FOR DUAL ELIGIBLE BENEFICIARIES

- TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY
- TABLE D.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH. BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP
- TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS. BY BENEFICIARY CHARACTERISTIC
- TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS. BY BRAND STATUS AND
- THERAPEUTIC CATEGORY
- TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,
- BY TOP 10 DRUG GROUP
- TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS. BY BENEFICIARY CHARACTERISTIC TABLE D.12, USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY
- BENEFICIARY CHARACTERISTIC
- TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

NATIONAL TABLES

- NATIONAL COMPARISON TABLE N.1a. OVERVIEW OF MEDICAID PHARMACY REIMBURSEMENT, ALL STATES COMBINED AND BY STATE, ALL
- MEDICAID BENEFICIARIES
- NATIONAL COMPARISON TABLE N.1b. OVERVIEW OF MEDICAID PHARMACY REIMBURSEMENT, ALL STATES COMBINED AND BY STATE,
- PERCENTAGE COMPARISONS, ALL MEDICAID BENEFICIARIES
- NATIONAL COMPARISON TABLE N.2. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, ALL STATES COMBINED AND BY STATE, ALL MEDICAID BENEFICIARIES
- NATIONAL COMPARISON TABLE N.3. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT BY BASIS OF ELIGIBILITY. ALL STATES COMBINED AND
- BY STATE, ALL MEDICAID BENEFICIARIES NATIONAL COMPARISON TABLE N.4. TOP 10 DRUG GROUPS RANKED BY TOTAL MEDICAID PHARMACY REIMBURSEMENT, ALL STATES COMBINED AND
- NATIONAL COMPARISON TABLE N.5. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT. ALL STATES COMBINED AND BY STATE, DUAL
- **ELIGIBLE BENEFICIARIES**

BY STATE, ALL MEDICAID BENEFICIARIES

NATIONAL COMPARISON TABLE N.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT BY BASIS OF ELIGIBILITY, ALL STATES COMBINED AND BY STATE, DUAL ELIGIBLE BENEFICIARIES
NATIONAL COMPARISON TABLE N.7. TOP 10 DRUG GROUPS RANKED BY TOTAL MEDICAID PHARMACY REIMBURSEMENT, ALL STATES COMBINED AND BY STATE, DUAL ELIGIBLE BENEFICIARIES

SUPPLEMENTAL TABLES

SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES
SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65
SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER

TABLE ND.2 CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY^{a, b} NONDUAL BENEFICIARIES, UNITED STATES, 2005

_			Number of	Beneficiaries				1	Number of Be	nefit Months		
Beneficiary						Other/						Other/
Characteristics	All	Aged	Disabled	Adults	Children	Unknown	All	Aged	Disabled	Adults	Children	Unknown
All	35,581,286	282,768	4,272,811	10,247,240	20,748,123	30,344	278,081,082	2,556,582	43,541,127	71,433,999	160,289,855	259,519
Age												
5 and younger	8,901,626	28	211,378	919	8,689,297	4	65,854,904	106	2,047,398	4,330	63,803,042	28
6-14	8,705,266	29	548,764	2,019	8,154,452	2	72,564,303	119	5,836,648	11,271	66,716,254	11
15-20	5,204,027	37	416,211	1,034,280	3,752,728	771	40,515,314	220	4,359,113	7,086,087	29,064,555	5,339
21-44	9,548,019	190	1,288,130	8,186,655	61,201	11,843	70,605,113	1,176	13,158,888	57,069,201	283,413	92,435
45-64	2,798,266	1,172	1,768,040	1,010,548	959	17,547	25,119,533	9,574	17,731,302	7,214,599	3,904	160,154
65-74	171,957	136,769	32,665	2,324	23	176	1,596,746	1,253,357	327,521	14,237	91	1,540
75-84	99,046	92,690	6,140	202	13	1	923,575	856,666	65,634	1,194	69	12
85 and older	53,390	51,722	1,469	169	30	0	450,300	434,811	14,538	717	234	0
Unknown	99,689	131	14	10,124	89,420	0	451,294	553	85	32,363	418,293	0
Gender												
Female	21,135,029	182,048	2,143,342	8,403,971	10,375,346	30,322	164,239,806	1,652,990	22,151,211	59,973,462	80,202,794	259,349
Male	14,361,882	100,477	2,129,236	1,838,976	10,293,171	22	113,330,412	901,632	21,388,029	11,450,849	79,589,732	170
Unknown	84,375	243	233	4,293	79,606	0	510,864	1,960	1,887	9,688	497,329	0
Race												
White	15,132,845	91,786	2,012,923	4,314,848	8,696,942	16,346	121,678,990	802,917	20,326,156	30,127,615	70,288,013	134,289
African American	8,576,247	45,681	1,137,154	2,174,093	5,214,991	4,328	70,605,862	411,717	11,600,214	15,618,952	42,937,447	37,532
Other/unknown	11,872,194	145,301	1,122,734	3,758,299	6,836,190	9,670	85,796,230	1,341,948	11,614,757	25,687,432	47,064,395	87,698
Use of Nursing Facilities ^c	, ,	,	, ,	, ,	, ,	,	, ,	, ,	, ,	, ,	, ,	,
Entire year	78,574	18,797	59,187	341	244	5	819.830	187,404	628,054	2,311	2,032	29
Part year	87.309	11.560	69,402	4,549	1,721	77	832,213	105.991	677,975	35,251	12,235	761
None	35,415,403	252.411	4,144,222	10,242,350	20,746,158	30,262	*	2,263,187	,	71,396,437	160,275,588	258,729
Maintenance Assistance Status	, ,	,	.,,===	,,		,		_,,	,,	,,		,
Cash	11,269,218	83 317	3,536,320	2,794,512	4,855,069	0	93,243,016	838,430	37,299,747	18,314,101	36,790,738	0
Medically needy	1,622,261	89.698	187,981	757,596	586,986	0	11,562,325	820,987	1,511,875	5,280,862	3,948,601	0
Poverty-related	12,919,918	37,582	173,819	1,302,619	11,375,554	30,344	99,715,594	298,175	1,323,291	6,965,233	90,869,376	259,519
Other/unknown	9,769,889	72,171	374,691	5,392,513	3,930,514	0,544	73,560,147	598,990	3,406,214	40,873,803	28,681,140	239,319
Dual Medicare Status	3,703,003	72,171	374,031	3,332,313	3,330,314	U	73,300,147	330,330	3,400,214	40,073,003	20,001,140	U
Full dual, part year	0	0	0	0	0	0	0	0	0	0	0	0
Non-dual, all year	-	-		10,247,240		30.344	278,081,082				160,289,855	259,519
Managed Care (MC) Status	.,,	- ,	, ,	., ,	., .,	/-	-/ /	,,-	7	,,	-,,	,
Fee-for-service (FFS) all year	26,266,896	263,783	3,843,255	7,692,894	14,436,941	30,023	232,161,989	2,445,464	40,636,761	59,417,460	129,404,663	257,641
FFS part year, with Rx claims	3,098,805	8,008	202,612	992,740	1,895,244	201	12,675,539	39,222	1,039,467	3,809,890	7,785,696	1,264
FFS part year, no Rx claims	4,282,772	6,428	97,349	1,056,402	3,122,501	92	12,150,128	19,341	344,776	2,847,987	8,937,680	344

a. Table ND.2 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

TABLE ND.3

ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC^{A, b}

NONDUAL BENEFICIARIES, UNITED STATES, 2005

Beneficiary	Percentage with	Mean Number			Mean \$, All Medicaid	Rx \$ as a Percentage of All Medicaid	Number of
Characteristics	at Least One Rx	of Rx	Mean Rx \$	\$ per Rx	FFS \$c	FFS \$d	Beneficiaries
All	56.2	7.3	\$515	\$71	\$3,211	16.0	35,581,286
Age							
5 and younger	58.4	3.6	172	47	1,997	8.6	8,901,626
6-14	54.2	4.2	311	75	1,787	17.4	8,705,266
15-20	51.1	4.3	320	74	2,572	12.5	5,204,027
21-44	53.8	7.6	559	74	3,681	15.2	9,548,019
45-64	73.5	31.0	2,355	76	10,353	22.7	2,798,266
65-74	70.3	25.8	1,668	65	9,865	16.9	171,957
75-84	64.8	25.2	1,540	61	10,301	14.9	99,046
85 and older	47.8	20.6	1,099	53	12,213	9.0	53,390
Unknown	9.4	0.4	19	43	513	3.7	99,689
Basis of Eligibilitye							
Aged	63.4	23.2	1,423	61	9,703	14.7	282,768
Disabled	77.8	28.9	2,538	88	13,934	18.2	4,272,811
Adults	50.4	5.3	296	56	1,965	15.1	10,247,240
Children	54.5	3.5	193	54	1,521	12.7	20,748,123
Unknown	71.5	15.4	1,479	96	9,165	16.1	30,344
Gender							
Female	56.9	7.6	489	64	2,962	16.5	21,135,029
Male	55.4	6.8	556	82	3,592	15.5	14,361,882
Unknown	12.7	0.7	37	56	694	5.3	84,375
Race							
White	62.1	9.5	656	69	3,657	17.9	15,132,845
African American	55.3	6.3	455	72	3,243	14.0	8,576,247
Other/unknown	49.3	5.1	379	74	2,620	14.5	11,872,194
Use of Nursing Facili	ities ^f						
Entire year	90.0	79.5	5,568	70	65,707	8.5	78,574
Part year	93.3	61.8	4,688	76	58,064	8.1	87,309
None	56.0	7.0	494	71	2,937	16.8	35,415,403
Maintenance Assista	nce Status						
Cash	62.5	12.7	1,001	79	5,474	18.3	11,269,218
Medically needy	59.0	8.0	551	69	4,554	12.1	1,622,261
Poverty related	58.4	4.0	208	52	1,660	12.5	12,919,918
Other/unknown	45.6	5.2	356	69	2,428	14.7	9,769,889

a. Table ND.3 includes beneficiaries represented by Cell K of Table 1.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV), the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.

d. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV), the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.

e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

e, interucate datas or engolinis, to classified use, acque, classified adoptive services. The children's group includes children's group children's group children's group children's group children's g

f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.4 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a, b} NONDUAL BENEFICIARIES, UNITED STATES, 2005

			_		Num	ber of Rx, Pe	ercentage	with:		_	Num	ber
Beneficiary Characteristics	Mean Number of Rx	Mean Rx \$	Rx \$ as a Percentage of All Medicaid FFS \$c	None	More than 0, but 1 or Less	More than 1, but 2 or Less		More than 5, but 10 or Less	More than 10	Mean \$, All Medicaid FFS \$ ^d	Beneficiaries	Benefit Months
All	0.9	\$66	16.0	43.8	41.2	6.0	5.8	2.3	0.8	\$411	35,581,286	278,081,082
Age												
5 and younger	0.5	23	8.6	41.6	50.4	4.8	2.4	0.5	0.2	270	8,901,626	65,854,904
6-14	0.5	37	17.4	45.8	45.4	4.7	3.3	0.6	0.2	214	8,705,266	72,564,303
15-20	0.6	41	12.5	48.9	41.3	5.2	3.6	0.8	0.2	330	5,204,027	40,515,314
21-44	1.0	76	15.2	46.2	35.8	7.2	7.4	2.6	0.8	498	9,548,019	70,605,113
45-64	3.4	262	22.7	26.5	20.7	10.9	22.2	14.5	5.3	1,153	2,798,266	25,119,533
65-74	2.8	180	16.9	29.7	23.3	11.8	20.7	11.1	3.4	1,062	171,957	1,596,746
75-84	2.7	165	14.9	35.2	19.0	10.5	20.5	11.7	3.0	1,105	99,046	923,575
85 and older	2.4	130	9.0	52.2	10.7	6.7	15.9	11.6	3.0	1,448	53,390	450,300
Unknown	0.1	4	3.7	90.6	5.8	1.3	1.4	0.6	0.2	113	99,689	451,294
Basis of Eligibility	_/ e											
Aged	2.6	157	14.7	36.6	20.5	10.6	19.0	10.4	2.9	1,073	282,768	2,556,582
Disabled	2.8	249	18.2	22.2	28.9	11.6	20.8	12.2	4.2	1,367	4,272,811	43,541,127
Adults	0.8	43	15.1	49.6	35.7	6.5	5.9	1.8	0.5	282	10,247,240	71,433,999
Children	0.5	25	12.7	45.5	46.7	4.5	2.5	0.5	0.2	197	20,748,123	160,289,855
Unknown	1.8	173	16.1	28.5	34.3	13.4	17.5	5.6	0.6	1,072	30,344	259,519
Gender												
Female	1.0	63	16.5	43.1	41.3	6.1	6.0	2.6	0.9	381	21,135,029	164,239,806
Male	0.9	71	15.5	44.6	41.2	5.8	5.6	2.0	0.7	455	14,361,882	113,330,412
Unknown	0.1	6	5.3	87.3	10.4	1.3	0.7	0.2	0.0	115	84,375	510,864
Race												
White	1.2	82	17.9	37.9	43.0	7.2	7.6	3.2	1.2	455	15,132,845	121,678,990
African American	0.8	55	14.0	44.7	42.6	5.4	4.9	1.8	0.6	394	8,576,247	70,605,862
Other/unknown	0.7	52	14.5	50.7	37.9	4.9	4.3	1.6	0.5	363	11,872,194	85,796,230
Use of Nursing Fa	icilities ^f											
Entire year	7.6	534	8.5	10.0	5.7	4.7	19.5	34.0	26.1	6,298	78,574	819,830
Part year	6.5	492	8.1	6.7	11.3	8.3	25.8	29.3	18.6	6,092	87,309	832,213
None	0.9	63	16.8	44.0	41.3	6.0	5.8	2.2	0.7	376	35,415,403	276,429,039
Maintenance Assi	stance Status	3										
Cash	1.5	121	18.3	37.5	38.8	7.7	9.8	4.7	1.6	662	11,269,218	93,243,016
Medically needy	1.1	77	12.1	41.0	39.2	7.8	8.0	3.0	1.0	639	1,622,261	11,562,325
Poverty related	0.5	27	12.5	41.6	49.0	5.3	3.1	0.8	0.3	215	12,919,918	99,715,594
Other/unknown from the MAX 2005 file for	0.7	47	14.7	54.4	34.0	4.7	4.6	1.7	0.6	323	9,769,889	73,560,147

a. Table ND.4 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV), the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.

d. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV), the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.

e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services.

f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.5 AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC^{a, b, c} NONDUAL BENEFICIARIES, UNITED STATES, 2005

		All Rx		Patented	l Branc Drugs	I-Name	Off-Pater	ıt Bran Drugs	d-Name	Gen	eric Dr	ugs
	Number			Number			Number			Number		
Characteristics	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx
All	0.9	\$66	\$71	0.4	\$50	\$142	0.0	\$4	\$82	0.5	\$12	\$23
Age												
5 and younger	0.5	23	47	0.2	17	110	0.0	1	40	0.3	5	17
6-14	0.5	37	75	0.2	30	129	0.0	2	70	0.2	5	21
15-20	0.6	41	74	0.2	33	146	0.0	2	69	0.3	6	21
21-44	1.0	76	74	0.4	57	160	0.0	4	92	0.6	14	23
45-64	3.4	262	76	1.3	198	148	0.1	14	116	2.0	50	25
65-74	2.8	180	65	1.2	141	119	0.1	6	72	1.5	33	22
75-84	2.7	165	61	1.2	130	111	0.1	5	60	1.4	30	21
85 and older	2.4	130	53	1.0	98	103	0.1	5	57	1.4	27	20
Unknown	0.1	4	43	0.0	3	150	0.0	0	45	0.1	1	14
Basis of Eligibility	d											
Aged	2.6	157	61	1.1	123	113	0.1	5	64	1.4	29	21
Disabled	2.8	249	88	1.1	195	172	0.1	12	115	1.6	41	26
Adults	0.8	43	56	0.3	30	119	0.0	3	74	0.5	10	20
Children	0.5	25	54	0.2	19	108	0.0	2	53	0.3	5	19
Unknown	1.8	173	96	0.6	138	220	0.1	6	106	1.1	27	24
Gender												
Female	1.0	63	64	0.4	47	131	0.0	4	77	0.6	13	22
Male	0.9	71	82	0.4	56	159	0.0	4	91	0.5	11	24
Unknown	0.1	6	56	0.0	5	148	0.0	0	41	0.1	1	18
Race												
White	1.2	82	69	0.5	62	137	0.1	5	87	0.7	15	23
African American	0.8	55	72	0.3	43	150	0.0	3	81	0.4	10	21
Other/unknown	0.7	52	74	0.3	40	148	0.0	3	73	0.4	9	23
Use of Nursing Fa	cilities ^e											
Entire year	7.6	534	70	2.8	403	145	0.3	24	78	4.5	106	24
Part year	6.5	492	76	2.2	366	163	0.3	27	106	4.0	98	25
None	0.9	63	71	0.3	48	142	0.0	3	82	0.5	11	22
Maintenance Assis	stance Stat	us										
Cash	1.5	121	79	0.6	93	159	0.1	6	101	0.9	21	24
Medically needy	1.1	77	69	0.4	58	140	0.0	4	86	0.7	15	23
Poverty related	0.5	27	52	0.2	20	106	0.0	2	51	0.3	6	19
Other/unknown	0.7	47	69	0.3	37	132	0.0	3	80	0.4	8	22

a. Table ND.5 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In the U.S., 0.4 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9ad778d7b6615 (October 26, 2007).

d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.6 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d} NONDUAL BENEFICIARIES, UNITED STATES, 2005

		ber of Rallonth Ame			\$ per	Benefit N Use		ong	•	\$ per	Rx			-		Userse	
Therapeutic Category	P Total	atented Brand- Name		Seneric		Patented Brand- Name	Off- Patent Brand- Name G	eneric	P Total	atented Brand- Name	Off- Patent Brand- Name (Generic	Total Number of Rx	Total Rx \$	Number of Users	As a Percentage of All Benes	Number of Benefit Months
Anti-infective Agents	0.3	0.1	0.0	0.2	\$19	\$13	\$2	\$4	\$70	\$177	\$74	\$22	33,804,060	\$2,374,728,767	12,845,957	36.1	125,628,859
Biologicals	0.3	0.3	0.0	0.0	296	262	12	22	1,082	1,048	2,057	1,233	308,105	333,249,767	113,028	0.3	1,124,579
Antineoplastic Agents	0.5	0.2	0.0	0.3	158	127	4	28	311	802	358	81	652,751	202,767,264	125,571	0.4	1,280,398
Endocrine/Metabolic Drugs	0.4	0.2	0.0	0.2	27	18	3	6	60	109	66	25	22,920,668	1,382,176,781	5,254,737	14.8	51,661,043
Cardiovascular Agents	1.1	0.5	0.0	0.7	52	40	0	11	46	87	43	17	30,764,819	1,416,097,489	2,674,082	7.5	27,253,509
Respiratory Agents	0.4	0.2	0.0	0.2	22	18	1	3	54	95	36	16	36,436,843	1,963,223,033	8,822,058	24.8	87,359,044
Gastrointestinal Agents	0.4	0.2	0.0	0.2	39	34	0	4	90	149	73	22	12,803,008	1,147,627,280	2,902,909	8.2	29,447,138
Genitourinary Agents	0.2	0.1	0.0	0.1	13	8	2	3	55	84	61	26	3,242,070	176,969,613	1,429,817	4.0	13,704,820
CNS Drugs	0.9	0.5	0.0	0.4	94	81	1	11	104	179	114	25	36,986,269	3,830,303,575	4,087,594	11.5	40,845,487
Stimulants/Anti-obesity/Anorexia	0.7	0.5	0.0	0.1	63	59	1	4	96	107	93	36	7,347,116	703,850,731	1,093,966	3.1	11,141,192
Miscellaneous Psychological/ Neurological Agents	0.4	0.3	0.0	0.1	126	120	0	5	310	356	112	81	558,120	173,253,191	131,673	0.4	1,376,863
Analgesics and Anesthetics	0.4	0.0	0.0	0.4	18	7	3	7	43	176	253	20	29,654,654	1,281,904,588	7,356,532	20.7	71,956,947
Neuromuscular Agents	0.7	0.2	0.0	0.4	58	41	3	15	87	166	106	37	16,034,989	1,393,477,854	2,321,481	6.5	23,869,364
Nutritional Products	0.3	0.0	0.0	0.2	6	2	0	4	19	32	26	16	4,857,925	91,354,812	1,825,605	5.1	16,397,804
Hematological Agents	0.5	0.2	0.0	0.3	133	127	1	5	249	608	41	17	3,520,058	877,191,051	664,138	1.9	6,572,397
Topical Products	0.2	0.1	0.0	0.2	11	7	0	4	47	90	55	24	17,192,925	804,043,760	7,256,992	20.4	72,416,362
Miscellaneous Products	0.3	0.1	0.0	0.1	53	39	6	8	199	282	346	72	821,195	163,042,154	297,183	0.8	3,063,307
Unknown Therapeutic Category	0.2	0.0	0.0	0.0	8	0	0	0	42	0	0	0	438,737	18,232,031	214,517	0.6	2,272,762
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	258,344,312	18,333,493,741	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2005 file for the U.S., released by CMS in 03/2009. This table was produced on 05/01/2009.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.6 includes the beneficiaries represented by Cell K of Table 1. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum

of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26 2007).

d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In the U.S., 0.4 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26 2007).

e. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2005.

TABLE ND.7 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP^{a, b, c} NONDUAL BENEFICIARIES, UNITED STATES, 2005

	· <u>-</u>		Users		An	nong Usei	rs
Top 10 Drug Groups	Total Medicaid Rx	Number of Users	As a Percentage of All Beneficiaries	Number of Benefit Months	Number of Rx per Benefit Month	\$ per Rx	Rx \$ per Benefit Month
ANTIPSYCHOTICS	\$2,465,940,686	1,699,024	4.8	18,268,784	0.6	\$230	\$135
ANTIASTHMATIC	1,272,918,120	6,327,795	17.8	64,780,492	0.3	70	20
ANTICONVULSANT	1,220,739,117	1,621,776	4.6	17,238,449	0.6	113	71
ANTIVIRAL	1,139,376,347	724,430	2.0	7,492,211	0.4	412	152
ANTIDEPRESSANTS	1,020,136,267	3,381,569	9.5	34,692,519	0.5	63	29
ULCER DRUGS	867,464,637	2,678,970	7.5	27,692,684	0.4	88	31
STIMULANTS/ANTI-OBESITY/ANOREXIANTS	689,087,089	1,256,036	3.5	13,136,800	0.5	96	52
ANALGESICS - Narcotic	666,731,713	6,307,022	17.7	63,148,747	0.3	39	11
ANTIDIABETIC	612,816,314	1,425,714	4.0	14,795,696	0.6	72	41
ANTIHYPERLIPIDEMIC	609,686,339	1,134,157	3.2	12,105,329	0.5	99	50
Total	10,564,896,629	26,556,493		273,351,711	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2005 file for the U.S., released by CMS in 03/2009. This table was produced on 05/01/2009.

a. Table ND.7 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$

⁼ Medicaid reimbursement; n.a. = not applicable.

TABLE ND.7A MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, UNITED STATES, 2005

All Top 10 Drug Groups ANTIPSYCHOTICS ANTIASTHMATIC

Beneficiary Characteristics	Number of Rx	Rx\$	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx per f Benefit	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx per F Benefit	Mean Rx \$ per Benefit Month
All	107,560,660	\$10,564,896,629	1,699,024	4.8	18,268,784	0.6	\$135	6,327,795	17.8	64,780,492	0.3	\$20
Female												
All Females	63,840,456	5,742,882,513	878,131	4.2	9,414,871	0.6	122	3,393,756	16.1	34,817,648	0.3	20
Female, Disabled												
All Ages	36,866,552	3,774,087,854	568,582	26.5	6,379,697	0.6	143	973,272	45.4	10,957,660	0.4	29
5 and younger	297,321	28,945,398	1,081	1.3	12,042	0.5	81	44,218	51.4	490,790	0.3	26
6-14	1,219,889	144,386,868	25,250	13.8	283,990	0.6	118	64,167	35.1	735,945	0.3	25
15-20	1,132,089	136,764,105	31,537	20.0	352,544	0.6	125	39,046	24.8	445,378	0.3	22
21-44	10,236,477	1,159,526,337	226,111	34.2	2,518,667	0.6	139	243,963	36.9	2,746,464	0.3	24
45-64	23,570,564	2,269,591,670	280,013	27.2	3,161,777	0.7	150	572,206	55.6	6,434,624	0.4	33
65-74	340,615	29,301,596	3,814	18.6	42,076	0.7	149	8,134	39.7	87,238	0.4	31
75-84	59,304	4,789,335	604	14.6	6,755	0.7	120	1,300	31.3	14,656	0.4	32
85 and older	10,293	782,545	172	16.0	1,846	0.6	94	238	22.2	2,565	0.3	24
Female, Other Eligibles												
All Ages	26,971,660	1,968,710,737	309,533	1.6	3,035,119	0.4	79	2,420,231	12.8	23,858,559	0.2	16
5 and younger	2,012,771	130,611,773	3,791	0.1	39,987	0.4	60	778,689	18.3	7,718,843	0.2	13
6-14	4,330,991	360,308,892	58,447	1.4	621,620	0.5	99	664,661	16.4	6,827,338	0.2	16
15-20	3,266,382	232,207,482	64,105	2.2	650,112	0.4	84	276,023	9.3	2,744,755	0.2	13
21-44	12,158,390	810,381,564	141,755	2.1	1,317,007	0.3	63	542,783	7.9	5,021,848	0.3	16
45-64	3,645,326	312,066,176	26,796	4.1	251,885	0.4	83	123,414	18.8	1,173,232	0.4	27
65-74	833,925	68,915,472	6,039	6.8	65,787	0.7	133	17,829	20.2	194,138	0.4	30
75-84	498,063	38,802,449	4,585	8.0	48,400	0.6	98	11,435	19.8	123,206	0.4	28
85 and older	225,812	15,416,929	4,015	10.9	40,321	0.6	81	5,397	14.7	55,199	0.4	24
Male												
All Males	43,707,473	4,821,162,906	820,720	5.7	8,852,417	0.6	149	2,931,664	20.4	29,942,767	0.3	19
Male, Disabled												
All Ages	25,220,040	3,147,400,167	549,817	25.8	6,125,120	0.7	166	626,830	29.4	6,980,853	0.4	29
5 and younger	480,208	46,027,039	4,026	3.2	44,271	0.5	84	72,862	58.2	809,504	0.3	26
6-14	2,962,419	350,951,810	84,198	23.0	948,229	0.6	128	134,866	36.8	1,542,698	0.3	24
15-20	1,866,143	247,904,716	63,673	24.6	715,200	0.6	148	55,549	21.5	635,713	0.3	23
21-44	7,428,641	1,073,680,181	220,776	35.3	2,447,354	0.7	181	104,494	16.7	1,162,479	0.4	24
45-64	12,290,106	1,410,717,443	174,467	23.6	1,940,709	0.7	174	253,927	34.4	2,775,920	0.5	35
65-74	162,146	15,550,143	2,288	18.8	24,997	0.8	167	4,309	35.4	45,176	0.5	35
75-84	26,286	2,279,279	325	16.3	3,658		149	707	35.5	8,072	0.4	31
85 and older	4,091	289,556	64	16.3	702	0.6	82	116	29.5	1,291	0.3	21

TABLE ND.7A MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, UNITED STATES, 2005

ANTIASTHMATIC

All Top 10 Drug Groups

NONDUAL BENEFICIARIES, UNITED STATES, 2008

ANTIPSYCHOTICS

	7 til Top To Blag Gloapo			7 (1 4 1 1 1	010110110				7 (1 4)	<i>17</i> (0 11 11 11 17 17 17 10	<u> </u>	
Beneficiary Characteristics	Number of Rx	Rx \$	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx per l Benefit	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx	Mean Rx \$ per Benefit Month
Male, Other Eligible	es											
All Ages	18,484,602	1,673,616,923	270,880	2.2	2,727,193	0.5	110	2,304,528	18.9	22,960,365	0.2	17
5 and younger	2,929,041	201,591,690	9,188	0.2	96,921	0.4	69	1,073,563	24.3	10,581,132	0.2	15
6-14	7,448,026	679,285,444	127,251	3.1	1,342,716	0.6	112	868,415	21.1	8,877,932	0.3	18
15-20	2,716,222	256,657,428	71,674	3.9	726,883	0.6	116	206,726	11.3	2,083,574	0.3	16
21-44	2,748,371	265,534,538	41,142	3.0	354,158	0.4	98	87,107	6.3	756,829	0.3	20
45-64	1,867,191	206,126,731	13,748	3.7	124,457	0.5	112	46,985	12.6	429,205	0.4	30
65-74	401,590	35,139,705	3,466	6.8	36,940	0.7	135	10,681	21.0	113,952	0.4	33
75-84	271,564	22,055,908	2,770	7.9	28,932	0.6	101	8,073	23.0	87,262	0.4	32
85 and older	102,597	7,225,479	1,641	10.8	16,186	0.6	86	2,978	19.6	30,479	0.4	26
Unknown	17,806	1,080,948	212	0.2	1,655	0.6	102	2,934	2.2	23,055	0.2	13

Source: Data for this table are from the MAX 2005 file for the U.S., released by CMS in 03/2009. This table was produced on 05/01/2009.

a. Table ND.7A includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7B MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,

BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, UNITED STATES, 2005

ANTICONVULSANT **ANTIVIRAL ANTIDEPRESSANTS** Mean Mean Number of Number Number of Number of Number Users Benefit Mean Users Benefit Users Benefit of Rx Mean of Rx as % Months per Rx \$ per Months as % per Rx \$ per as % Mean Months of All of All Benefit Benefit Number of Among Number Mean Number of Benefit Number of Among of All Among Benefit **Beneficiary Characteristics** Rx\$ Users Benes Users Month Month Users Benes Users of Rx Users Benes Users Month Month 7,492,211 ΑII 1,621,776 4.6 17,238,449 0.6 \$71 724,430 2.0 \$152 3,381,569 9.5 34,692,519 0.5 \$29 **Female** 116 2,386,941 All Females 983,299 4.7 10,409,485 0.6 67 431,911 2.0 4,427,371 0.3 11.3 24,360,967 0.5 29 Female, Disabled All Ages 607.956 28.4 6.808.190 0.7 76 134.322 6.3 1.502.619 0.5 218 1.103.407 51.5 12.313.220 0.5 34 91 2.1 45 5 and younger 8,862 10.3 98,464 0.7 1,833 20,708 0.3 653 0.8 7,331 0.4 11 23 6-14 34,001 18.6 386,837 8.0 111 5,779 3.2 66,673 0.4 156 19,933 10.9 224,778 0.5 15-20 33,118 21.0 374,410 8.0 114 5,438 3.4 62,077 0.3 130 38,202 24.2 426,410 0.5 28 2,500,873 33 21-44 224,309 33.9 0.7 85 55,626 8.4 615,665 0.5 221 376,917 56.9 4,182,138 0.5 45-64 303,531 29.5 3,402,408 0.6 62 65,076 6.3 731,220 0.5 235 660,428 64.2 7,393,094 0.6 36 65-74 3,499 17.1 0.7 46 490 2.4 5,360 0.3 126 6,140 30.0 31 38,069 66,727 0.6 75-84 540 13.0 6.083 0.6 36 68 1.6 775 0.4 108 938 22.6 10.591 0.6 30 85 and older 96 8.9 1,046 0.5 24 12 1.1 141 0.1 6 196 18.2 2,151 0.6 34 Female, Other Eligibles All Ages 375,337 2.0 3,601,281 0.5 48 297,544 1.6 2,924,548 0.2 63 1,283,400 6.8 12,047,255 0.4 24 5 and younger 10,514 0.2 105,231 0.5 54 38,446 0.9 404,759 0.1 7 3,382 0.1 34,579 0.3 10 25 6-14 39,533 1.0 411,519 0.5 69 49,672 1.2 531,565 0.1 89,387 2.2 940,758 0.4 20 32 15-20 50.251 1.7 502.211 0.5 63 42.641 1.4 421.866 0.2 193.893 6.6 1.910.396 0.3 20 21-44 214,849 3.1 1,997,105 41 145,015 2.1 0.3 84 808,125 7,374,154 24 0.4 1,347,814 11.8 0.4 45-64 46,006 7.0 432.759 0.5 44 18,987 2.9 188.082 0.4 206 156,971 23.9 1.449.894 0.5 32 15,790 65-74 7,582 8.6 82,456 0.6 40 1,449 1.6 16,076 0.2 69 17.9 171,413 0.5 27 75-84 4,578 7.9 49,377 0.6 33 820 9,080 0.2 34 17.1 105,885 29 1.4 9,874 0.5 9 85 and older 2,024 5.5 20,623 0.7 31 514 1.4 5,306 0.1 5,978 16.3 60,176 0.7 32 Male All Males 638,339 4.5 6,827,747 0.7 77 292,386 2.0 3,063,764 0.4 205 994,270 6.9 10,329,039 0.5 29 Male, Disabled All Ages 449,722 21.1 5,000,069 0.7 85 140,024 6.6 1,512,909 0.6 312 573,547 26.9 6,300,065 0.5 32 12.068 9.6 134.098 0.7 87 2.0 0.2 34 1.448 1.2 12 5 and younger 2.445 27,758 16.160 0.4 6-14 58,472 16.0 664,273 0.7 97 8,055 2.2 92,855 0.4 122 48,225 13.2 545,529 0.5 24 15-20 46,308 17.9 524,431 8.0 111 4,843 1.9 55,667 0.3 141 47,876 18.5 536,790 0.5 30 21-44 169,122 27.0 1.877.670 0.8 95 54.795 8.8 573,805 0.6 308 201,575 32.2 2,198,102 0.5 34 9.4 361 271,445 33 45-64 161,605 21.9 1,776,864 0.7 62 69,444 758,241 0.7 36.8 2,971,559 0.5 65-74 1,851 15.2 19,468 0.7 51 399 3.3 4,067 0.5 236 2,522 20.7 26,814 0.6 34 75-84 258 13.0 2,871 0.7 42 37 1.9 444 0.3 90 374 18.8 4,209 0.5 29 1.5 7 38 9.7 394 0.7 46 6 72 0.1 82 20.9 902 0.7 35 85 and older

TABLE ND.7B MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,

BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, UNITED STATES, 2005

		ANTI	CONVULSAN	NT			AN	ITIVIRAL				ANTID	EPRESSAN ⁻	ΓS	
Beneficiary Characteristics	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx per I Benefit	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among N	Mean Number of Rx			Users as % of All Benes	Number of Benefit Months Among Users	of Rx per f Benefit	
Male, Other Eligibles															
All Ages	188,602	1.5	1,827,604	0.5	57	152,306	1.2	1,550,629	0.3	101	420,578	3.4	4,028,426	0.4	25
5 and younger	14,628	0.3	147,991	0.4	49	40,132	0.9	421,342	0.1	7	4,992	0.1	51,582	0.3	10
6-14	57,431	1.4	600,733	0.6	65	46,351	1.1	496,724	0.1	23	120,372	2.9	1,262,222	0.4	21
15-20	36,932	2.0	368,935	0.6	71	17,303	0.9	177,130	0.2	44	100,459	5.5	995,982	0.4	25
21-44	50,432	3.6	434,813	0.5	46	30,177	2.2	275,011	0.6	258	126,122	9.1	1,080,882	0.4	26
45-64	21,870	5.9	197,324	0.5	46	16,745	4.5	162,942	0.7	380	54,995	14.8	493,897	0.5	30
65-74	3,791	7.4	40,837	0.6	45	894	1.8	9,739	0.3	124	6,314	12.4	67,783	0.5	28
75-84	2,533	7.2	27,075	0.6	35	465	1.3	5,197	0.2	29	4,714	13.4	50,038	0.6	30
85 and older	985	6.5	9,896	0.6	31	239	1.6	2,544	0.1	14	2,610	17.2	26,040	0.7	33
Unknown	159	0.1	1,305	0.6	57	234	0.2	1,506	0.3	59	637	0.5	3,553	0.6	32

Source: Data for this table are from the MAX 2005 file for the U.S., released by CMS in 03/2009. This table was produced on 05/01/2009.

a. Table ND.7B includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7C MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY,

BY SEX, BASIS OF ELIGIBILITY, AND AGEa, b, c NONDUAL BENEFICIARIES, UNITED STATES, 2005

		UL	CER DRUGS					TI-OBESITY/		NTS		ANALO	GESICS - Nar	cotic	
Beneficiary	Number of	Users as % of All	Number of Benefit N Months Among	Mean lumber of Rx per I Benefit		Number of	Users as % of All	Number of Benefit N Months Among		Mean Rx \$ per Benefit	Number of	Users as % of All	Number of Benefit N Months Among		Mean Rx \$ per Benefit
Characteristics	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	
All	2,678,970	7.5	27,692,684	0.4	\$31	1,256,036	3.5	13,136,800	0.5	\$53	6,307,022	17.7	63,148,747	0.3	\$11
Female															
All Females	1,772,794	8.4	18,407,265	0.3	31	385,955	1.8	4,037,247	0.5	51	4,467,321	21.2	44,424,911	0.3	(
Female, Disabled	d														
All Ages	774,293	36.1	8,739,312	0.4	42	88,285	4.1	991,891	0.5	57	1,338,676	62.5	14,990,670	0.4	19
5 and younger	14,061	16.3	149,622	0.4	28	2,059	2.4	22,359	0.4	40	6,706	7.8	76,363	0.1	•
6-14	16,803	9.2	193,642	0.4	39	40,182	22.0	451,919	0.6	53	19,382	10.6	223,800	0.1	2
15-20	20,350	12.9	232,432	0.3	29	14,921	9.5	168,918	0.5	53	43,149	27.4	491,372	0.2	3
21-44	203,783	30.8	2,303,736	0.4	35	16,676	2.5	185,954	0.5	61	471,081	71.2	5,266,645	0.3	17
45-64	507,920	49.3	5,733,452	0.5	45	14,383	1.4	162,075	0.5	70	786,848	76.4	8,806,313	0.4	22
65-74	9,228	45.1	102,192	0.5	42	60	0.3	626	0.5	54	9,365	45.7	101,953	0.4	13
75-84	1,783	43.0	20,208	0.5	43	3	0.1	28	0.6	29	1,754	42.3	19,901	0.3	10
85 and older	365	34.0	4,028	0.5	47	1	0.1	12	0.2	34	391	36.4	4,323	0.3	8
Female, Other El	ligibles														
All Ages	998,229	5.3	9,666,777	0.3	22	297,666	1.6	3,045,341	0.5	49	3,127,960	16.5	29,431,161	0.2	4
5 and younger	122,216	2.9	1,094,997	0.2	11	11,747	0.3	122,766	0.3	32	104,803	2.5	1,102,597	0.1	
6-14	111,411	2.8	1,180,968	0.2	12	199,655	4.9	2,074,559	0.5	49	225,901	5.6	2,400,969	0.1	
15-20	130,665	4.4	1,310,803	0.2	12	48,248	1.6	494,895	0.5	49	541,615	18.3	5,233,257	0.2	2
21-44	448,922	6.5	4,244,421	0.3	22	32,954	0.5	305,629	0.4	50	1,997,597	29.1	18,202,595	0.2	ţ
45-64	130,124	19.8	1,243,169	0.4	39	4,793	0.7	44,655	0.5	67	212,272	32.3	1,999,564	0.3	12
65-74	29,365	33.3	318,973	0.4	41	120	0.1	1,331	0.5	63	24,275	27.5	265,050	0.3	9
75-84	17,732	30.8	193,246	0.4	42	82	0.1	868	0.4	41	14,589	25.3	157,665	0.3	8
85 and older	7,794	21.2	80,200	0.6	44	67	0.2	638	0.5	34	6,908	18.8	69,464	0.4	13
Male															
All Males	905,126	6.3	9,277,636	0.4	32	869,958	6.1	9,098,332	0.6	53	1,838,745	12.8	18,717,547	0.3	13
Male, Disabled															
All Ages	428,099	20.1	4,732,818	0.5	41	215,788	10.1	2,420,124	0.6	57	777,605	36.5	8,478,331	0.4	23
5 and younger	18,108	14.5	193,788	0.4	29	7,389	5.9	81,071	0.4	33	11,144	8.9	126,625	0.1	
6-14	24,457	6.7	282,246	0.4	38	142,634	39.0	1,599,169	0.6	56	33,673	9.2	389,226	0.1	2
15-20	21,942	8.5	250,211	0.4	34	46,350	17.9	525,584	0.6	60	47,746	18.5	544,598	0.2	
21-44	117,099	18.7	1,300,642	0.4	39	13,617	2.2	150,933	0.6	62	259,143	41.4	2,817,495	0.3	20
45-64	241,326	32.7	2,649,538	0.5	44	5,762	0.8	62,983	0.5	71	420,892	57.0	4,547,262	0.5	
65-74	4,266	35.0	46,136	0.5	42	31	0.3	324	0.5	73	4,194	34.4	43,841	0.4	
75-84	764	38.4	8,711	0.5	46	5	0.3	60	0.2	16	682	34.3	7,802	0.3	
85 and older	137	34.9	1,546	0.5	43	0	0.0	0	0.0	0	131	33.3	1,482	0.3	

TABLE ND.7C MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY,

BY SEX, BASIS OF ELIGIBILITY, AND AGEa, b, c NONDUAL BENEFICIARIES, UNITED STATES, 2005

		UL	CER DRUGS			STIMULA	NTS/AN	TI-OBESITY/A	NOREXIA	NTS		ANALO	GESICS - Nard	cotic	
		Users	Number of Benefit N	Mean umber of	Mean		Users	Number of Benefit N	Mean lumber of	Mean		Users	Number of Benefit N	Mean Jumber of	Mean
		as %	Months		Rx \$ per		as %	Months		Rx \$ per		as %	Months		Rx \$ per
Beneficiary Characteristics	Number of Users	of All Benes	Among Users	Benefit Month	Benefit Month	Number of Users	of All Benes	Among Users	Benefit Month	Benefit Month	Number of Users	of All Benes	Among Users	Benefit Month	Benefit Month
Male, Other Elig	ibles														
All Ages	476,736	3.9	4,543,692	0.3	22	654,162	5.4	6,678,166	0.5	52	1,060,332	8.7	10,235,735	0.2	6
5 and younger	144,187	3.3	1,289,219	0.2	12	32,368	0.7	338,501	0.4	30	143,369	3.2	1,505,494	0.1	1
6-14	94,038	2.3	997,966	0.2	14	506,114	12.3	5,182,120	0.6	52	231,822	5.6	2,459,627	0.1	1
15-20	59,221	3.2	602,253	0.2	15	104,024	5.7	1,057,929	0.5	56	237,903	13.0	2,384,249	0.1	2
21-44	94,931	6.9	840,772	0.3	33	9,430	0.7	79,389	0.5	55	325,435	23.5	2,760,917	0.3	12
45-64	58,241	15.6	534,296	0.4	42	2,072	0.6	18,634	0.5	70	100,174	26.9	896,223	0.4	18
65-74	13,360	26.2	142,974	0.4	41	66	0.1	672	0.4	59	11,227	22.0	119,654	0.3	10
75-84	9,286	26.4	100,602	0.4	43	61	0.2	636	0.5	35	7,372	21.0	79,242	0.3	9
85 and older	3,472	22.9	35,610	0.6	45	27	0.2	285	0.5	27	3,030	20.0	30,329	0.4	13
Unknown	1,613	1.2	10,085	0.3	14	135	0.1	1,278	0.5	45	2,449	1.9	12,850	0.3	4

Source: Data for this table are from the MAX 2005 file for the U.S., released by CMS in 03/2009. This table was produced on 05/01/2009.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.7C includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26 2007).

TABLE ND.7D MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS

SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, UNITED STATES, 2005

		1A	NTIDIABETIC				ANTIH	IYPERLIPIDEI	ИIC			
Beneficiary Characteristics	Number of Users	Users as % of All Benes	Number of Benefit N Months Among Users	Mean Number of Rx per I Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit N Months Among Users	Mean lumber of Rx per F Benefit Month	Mean Rx \$ per Benefit Month	Number of Beneficiaries	Number of Benefit Months
All	1,425,714	4.0	14,795,696	0.6	\$41	1,134,157	3.2	12,105,329	0.5	\$50	35,581,286	278,081,082
Female												
All Females	951,855	4.5	9,952,610	0.6	41	707,691	3.4	7,635,090	0.5	50	21,112,598	164,162,001
Female, Disable	d											
All Ages	586,725	27.4	6,558,283	0.6	44	471,149	22.0	5,322,331	0.5	52	2,143,340	22,151,198
5 and younger	317	0.4	3,433	0.6	62	239	0.3	2,603	0.2	7	86,106	832,830
6-14	2,903	1.6	32,719	0.6	57	324	0.2	3,720	0.4	28	182,608	1,950,297
15-20	5,666	3.6	63,850	0.6	46	1,022	0.6	11,492	0.4	34	157,649	1,647,861
21-44	100,258	15.1	1,121,992	0.5	39	67,279	10.2	761,529	0.5	44	661,874	6,871,317
45-64	465,116	45.2	5,198,462	0.6	45	392,161	38.1	4,428,748	0.5	54	1,029,401	10,584,476
65-74	10,399	50.8	114,375	0.6	40	8,421	41.1	94,570	0.6	58	20,479	209,380
75-84	1,828	44.1	20,870	0.6	37	1,516	36.5	17,526	0.6	60	4,149	44,450
85 and older	238	22.2	2,582	0.6	35	187	17.4	2,143	0.6	64	1,074	10,587
Female, Other E	ligibles											
All Ages	365,093	1.9	3,394,151	0.5	35	236,520	1.2	2,312,631	0.4	44	18,969,258	142,010,803
5 and younger	1,737	0.0	16,857	0.7	55	3,466	0.1	31,052	0.1	3	4,247,343	31,167,937
6-14	15,564	0.4	155,180	0.7	57	1,257	0.0	12,934	0.3	25	4,048,587	33,101,334
15-20	22,168	0.7	211,524	0.5	41	2,907	0.1	29,022	0.3	25	2,958,574	22,122,439
21-44	165,061	2.4	1,463,571	0.5	31	78,246	1.1	746,307	0.4	35	6,874,152	49,103,186
45-64	106,622	16.2	971,001	0.6	37	99,412	15.1	936,052	0.5	48	657,944	4,860,249
65-74	31,831	36.0	338,987	0.6	36	30,911	35.0	334,797	0.5	53	88,298	814,800
75-84	17,214	29.9	185,976	0.6	33	16,529	28.7	181,800	0.5	55	57,665	535,064
85 and older	4,896	13.3	51,055	0.6	31	3,792	10.3	40,667	0.6	54	36,695	305,794
Male												
All Males	473,709	3.3	4,841,908	0.6	43	426,386	3.0	4,469,413	0.5	51	14,338,146	113,249,787
Male, Disabled												
All Ages	304,642	14.3	3,311,648	0.6	43	282,785	13.3	3,133,244	0.5	53	2,129,227	21,387,975
5 and younger	342	0.3	3,590	0.6	56	309	0.2	3,379	0.2	6	125,265	1,214,485
6-14	3,412	0.9	38,300	0.7	58	533	0.1	6,077	0.4	26	366,141	3,886,192
15-20	4,721	1.8	53,096	0.6	54	1,564	0.6	17,838	0.4	35	258,559	2,711,216
21-44	57,563	9.2	629,296	0.6	42	57,842	9.2	648,800	0.5	47	626,206	6,287,121
45-64	233,364	31.6	2,530,270	0.6	43	218,076	29.5	2,408,027	0.6	55	738,494	7,145,755
65-74	4,468	36.7	48,131	0.6	39	3,799	31.2	41,494	0.6	58	12,180	118,090
75-84	684	34.4	7,966	0.6	38	601	30.2	6,951	0.6	61	1,989	21,170
85 and older	88	22.4	999	0.6	27	61	15.5	678	0.6	69	393	3,946

TABLE ND.7D MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS

SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, UNITED STATES, 2005

		ΙA	NTIDIABETIC				ANTIF	IYPERLIPIDE	ИIC			
		Users	Number of Benefit N	Mean lumber of	Mean		Users	Number of Benefit N	Mean lumber of	Mean		
Dfi-i	Ni wala a wa a f	as %	Months		Rx \$ per	Nicosale a mark	as %	Months		Rx \$ per	Niverband	Ni wasia a wasif
Beneficiary Characteristics	Number of Users	of All Benes	Among Users	Benefit Month	Benefit Month		of All Benes	Among Users	Benefit Month	Benefit Month	Number of Beneficiaries I	Number of Benefit Months
Male, Other Elig	ibles											
All Ages	169,000	1.4	1,530,054	0.6	43	143,590	1.2	1,336,106	0.5	46	12,208,919	91,861,812
5 and younger	2,322	0.1	22,551	0.6	51	3,975	0.1	35,995	0.1	4	4,414,244	32,439,254
6-14	12,440	0.3	123,723	0.7	61	1,781	0.0	18,639	0.3	24	4,106,797	33,617,107
15-20	11,384	0.6	108,122	0.7	67	2,577	0.1	26,094	0.3	29	1,828,768	14,029,974
21-44	48,715	3.5	404,174	0.5	40	43,299	3.1	382,060	0.4	39	1,385,610	8,342,229
45-64	68,290	18.3	597,696	0.6	40	66,301	17.8	595,687	0.5	51	372,267	2,527,882
65-74	14,911	29.3	157,158	0.6	36	15,101	29.7	161,706	0.5	55	50,919	453,790
75-84	8,689	24.7	93,390	0.6	34	8,849	25.2	97,667	0.5	57	35,148	322,055
85 and older	2,249	14.8	23,240	0.6	33	1,707	11.3	18,258	0.6	57	15,166	129,521
Unknown	254	0.2	1.560	0.7	40	113	0.1	1.017	0.5	42	130.542	669.294

Source: Data for this table are from the MAX 2005 file for the U.S., released by CMS in 03/2009. This table was produced on 05/01/2009.

a. Table ND.7D includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.8 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,

BY BENEFICIARY CHARACTERISTIC^{a, b} NONDUAL BENEFICIARIES, UNITED STATES, 2005

Beneficiary		Number of Py per Repetit	Number of All-Year Nursing	Benefit Months Among All- Year Nursing Facility
Characteristics	Rx \$ per Benefit Month	Month	· ·	Residents
All	\$534	7.6	78,574	819,830
Age				
0-64	596	8.1	56,832	601,450
65-74	470	7.2	6,731	70,796
75-84	359	6.4	6,912	69,731
85 and older	267	5.3	8,098	77,850
Unknown	662	16.0	1	3
Gender				
Female	540	8.0	41,028	432,326
Male	527	7.2	37,486	387,049
Unknown	364	6.7	60	455
Race				
White	551	8.3	41,939	430,182
African American	539	7.3	22,023	234,679
Other/unknown	478	6.3	14,612	154,969
Basis of Eligibility	С			
Aged	352	6.3	18,797	187,404
Disabled	587	8.0	59,187	628,054
Adults	761	4.5	341	2,311
Children	498	5.9	244	2,032
Unknown	597	8.7	5	29

Source: Data for this table are from the MAX 2005 file for the U.S., released by CMS in 03/2009. This table was produced on 05/01/2009.
a. Table ND.8 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their 2005 Medicaid enrollment. A total of 87,309 beneficiaries who were in nursing facilities for part of their enrollment and their 832,213 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.9 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,

BY BRAND STATUS AND THERAPEUTIC CATEGORYA, b, c, d, e NONDUAL BENEFICIARIES, UNITED STATES, 2005

Number of Rx per Benefit \$ per Benefit Month Among Month Among Users Users \$ per Rx Users

Therapeutic Category	P	atented Brand- Name		Seneric		atented Brand- Name	Off- Patent Brand- Name Ger	neric	F	Patented Brand- Name	Off- Patent Brand- Name (Generic	Total Number of Rx	Total Rx \$	Number of Users	As a Percentage of All-Year Nursing Facility Residents	Number of Benefit Months
Anti-infective Agents	0.6	0.3	0.1	0.3	\$83	\$67	\$7	\$9	\$138	\$268	\$121	\$31	300,632	\$41,352,724	45,963	58.5	496,490
Biologicals	0.1	0.1	0.0	0.0	12	10	1	2	120	134	1,348	73	12,246	1,469,639	10,164	12.9	118,516
Antineoplastic Agents	0.6	0.1	0.0	0.5	91	40	1	50	165	594	344	103	26,639	4,405,827	4,699	6.0	48,235
Endocrine/Metabolic Drugs	1.3	0.5	0.1	0.7	63	45	7	12	48	92	47	17	451,562	21,695,419	31,861	40.5	341,792
Cardiovascular Agents	2.2	0.7	0.0	1.5	75	51	1	23	35	76	35	16	1,068,840	37,084,249	46,719	59.5	494,284
Respiratory Agents	1.0	0.4	0.0	0.5	48	38	1	9	50	94	53	17	313,632	15,669,624	30,627	39.0	328,232
Gastrointestinal Agents	1.2	0.5	0.0	0.7	72	57	1	13	62	122	66	20	514,326	31,722,464	41,641	53.0	443,328
Genitourinary Agents	0.7	0.4	0.0	0.3	42	33	1	8	61	83	55	29	116,181	7,101,663	15,576	19.8	170,940
CNS Drugs	2.1	1.1	0.0	1.0	225	197	2	26	105	181	78	26	1,312,218	138,263,393	57,011	72.6	613,607
Stimulants/Anti-obesity/Anorexia	0.8	0.3	0.0	0.5	57	49	1	8	73	159	64	17	8,054	591,157	968	1.2	10,303
Miscellaneous Psychological/ Neurological Agents	0.9	0.9	0.0	0.0	190	190	0	1	201	202	71	81	87,211	17,498,877	8,588	10.9	91,883
Analgesics and Anesthetics	1.3	0.2	0.1	1.0	64	26	16	22	51	127	149	23	509,508	25,788,899	37,982	48.3	400,930
Neuromuscular Agents	1.6	0.4	0.1	1.1	112	62	6	44	69	147	81	39	696,910	48,309,555	39,324	50.0	432,499
Nutritional Products	0.8	0.0	0.1	0.7	17	1	1	14	20	52	20	19	187,652	3,810,515	21,741	27.7	228,771
Hematological Agents	1.2	0.4	0.1	0.8	109	98	1	9	90	255	17	12	307,936	27,775,432	24,711	31.4	255,475
Topical Products	0.6	0.2	0.0	0.4	29	18	3	8	45	77	57	23	285,864	12,892,524	40,358	51.4	442,840
Miscellaneous Products	0.4	0.1	0.0	0.3	22	10	1	11	56	155	153	33	28,279	1,581,618	6,889	8.8	72,944
Unknown Therapeutic Category	0.4	0.0	0.0	0.0	11	0	0	0	31	0	0	0	15,999	496,294	4,085	5.2	45,059
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	6,243,689	437,509,873	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2005 file for the U.S., released by CMS in 03/2009. This table was produced on 05/01/2009.

In the U.S., 0.4 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement

a. Table ND.9 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 87,309 beneficiaries who were

in nursing facilities for part of their enrollment and their 832,213 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2005. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615

e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.10 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,

BY TOP 10 DRUG GROUP^{a, b, c, d} NONDUAL BENEFICIARIES, UNITED STATES, 2005

			Users	_	Among Users		
Top 10 Drug Groups in Nursing Facilities	Total Medicaid Rx\$	Number of Users	As a Percentage of All-Year Nursing Facility Residents	Number of Benefit Monthsp	Number of Rx er Benefit Month	\$ per Rx	Rx \$ per Benefit Month
ANTIPSYCHOTICS	\$106,215,900	50,923	64.8	572,204	1.0	\$195	\$186
ANTICONVULSANT	40,166,511	42,529	54.1	473,216	1.1	79	85
ANTIDEPRESSANTS	25,867,915	49,771	63.3	542,240	0.8	56	48
ANTIVIRAL	24,849,878	8,098	10.3	89,480	0.7	386	278
ULCER DRUGS	24,733,830	42,079	53.6	452,418	0.8	71	55
MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL	17,587,578	10,876	13.8	116,620	0.8	196	151
ANTIDIABETIC	17,304,909	35,377	45.0	384,116	0.9	49	45
ANALGESICS - Narcotic	14,812,019	39,588	50.4	412,546	0.9	42	36
ANTIHYPERLIPIDEMIC	14,489,860	19,055	24.3	211,001	0.8	86	69
HEMATOPOIETIC AGENTS	14,075,623	16,937	21.6	179,539	0.7	113	78
Total	300,104,023	315,233		3,433,380	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2005 file for the U.S., released by CMS in 03/2009. This table was produced on 05/01/2009.

a. Table ND.10 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 87,309 beneficiaries who were in nursing facilities for part of their enrollment and their 832,213 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

Group. Therefore, the sum of users across duly groups may exceed the local humber of individual users. Benefit minitials after finitials duling which beneficial resolutions and the following manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26 2007).

Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$= Medicaid reimbursement.

TABLE ND.10A

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d} NONDUAL BENEFICIARIES, UNITED STATES, 2005

All Top 10 Drug Groups **ANTIPSYCHOTICS** ANTICONVULSANT Users as % Number of Users as % Number of of All-Year Benefit of All-Year Benefit Months Months Mean Nursing Mean Nursing Beneficiary Number of Facility Among Number Mean Number of Facility Among Number Mean Rx\$ Residents Residents Characteristics Number of Rx Users Users of Rx Rx\$ Users Users of Rx Rx\$ ΑII 3.012.652 \$300.104.023 50.923 64.8 572.204 1.0 \$186 42.529 54.1 473.216 1.1 \$85 Female All Females 1,650,256 159,800,838 26,979 65.8 304,577 1.0 184 22,209 54.1 248,404 1.1 84 Female, Disabled All Ages 1,317,719 132,975,545 21,380 74.5 244,202 1.0 196 18,945 66.0 213,675 1.1 89 64 or younger 1,257,441 127,347,488 20,092 74.6 229,669 1.0 198 18,178 67.5 205,285 1.1 90 65-74 47,698 4,506,099 1,002 76.1 11,316 1.0 182 645 49.0 7,047 1.0 68 75-84 9.955 879.981 219 65.0 2.469 0.9 149 99 29.4 1.096 0.9 50 85 and older 2,625 241,977 67 60.4 748 0.7 108 23 20.7 247 8.0 38 Female, Other Eligibles 332,537 26,825,293 5,599 45.5 60,375 8.0 3,264 34,729 57 All Ages 137 26.5 1.0 3,858 636,365 45 17.0 446 0.8 228 87 33.0 809 1.2 110 64 or younger 65-74 108,701 9,600,988 1,792 69.3 20,205 0.9 183 1,324 51.2 14,544 1.0 67 110,922 75-84 8,621,720 1,798 46.1 19,358 8.0 130 1,054 27.0 11,189 0.9 54 85 and older 109,056 7,966,220 1,964 35.3 20,366 0.7 94 799 14.4 8,187 0.9 40 Male All Males 1,361,092 140,208,664 23,916 267,352 20,303 224,643 63.8 0.9 187 1.1 86 Male, Disabled All Ages 1,175,721 124,299,407 20,733 68.0 233,802 1.0 194 18,330 60.2 203,808 1.1 88 1,139,712 19.841 67.8 223.819 1.0 194 17.801 60.8 198.088 89 64 or younger 120,676,798 1.1 65-74 29.194 3,013,317 740 76.7 8.284 0.9 184 441 45.7 4.808 1.0 72 75-84 5,171 496,304 117 63.6 1,309 0.9 176 75 40.8 798 58 1.1 85 and older 1,644 112,988 35 61.4 390 8.0 99 13 22.8 114 0.9 39 Male, Other Eligibles All Ages 185,343 15.908.036 3.183 45.4 33.550 0.8 142 1.973 28.1 20.835 1.0 59 64 or younger 6,039 1,273,878 71 20.2 685 8.0 214 112 31.8 1,158 1.0 86 65-74 61.319 5,362,438 1.104 59.6 12.050 0.9 170 802 43.3 8.766 1.0 69 75-84 69,629 5,597,343 1,185 47.9 12,500 8.0 136 691 28.0 7,291 0.9 53 85 and older 48,356 3,674,377 823 35.2 8.315 8.0 105 368 15.7 3,620 0.9 41 Unknown 1.332 95.742 28 45.9 275 0.7 81 17 27.9 169 0.7 47

a. Table ND.10A includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 87,309 beneficiaries who were in nursing facilities for part of their enrollment and their 832,213 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10B

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY

AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGEA, b, c, d

NONDUAL BENEFICIARIES, UNITED STATES, 2005

		ANTIDE	PRESSANTS	3			ANT	IVIRAL				ULCEF	R DRUGS		
Beneficiary Characteristics	Number of Users	Year Nursing Facility	Number of Benefit Months Among Users			Number of Users	Users as % of All- Year Nursing Facility Residents	Number of Benefit Months Among Users			Number of Users	Users as % of All- Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	
All	49,771	63.3	542,240	0.8	\$48	8,098	10.3	89,480	0.7	\$278	42,079	53.6	452,418	0.8	\$55
Female															
All Females	28,203	68.7	309,128	0.9	49	3,500	8.5	38,881	0.6	207	22,451	54.7	243,791	0.8	5
Female, Disable	ed														
All Ages	21,549	75.1	239,264	0.9	51	2,914	10.1	32,576	0.7	235	16,635	57.9	182,867	0.8	56
64 or younger	20,687	76.8	230,031	0.9	51	2,858	10.6	31,982	0.7	238	15,691	58.2	172,889	0.8	56
65-74	650	49.4	6,925	0.8	45	43	3.3	449	0.2	78	729	55.4	7,672	0.7	54
75-84	154	45.7	1,682	0.8	43	8	2.4	85	0.1	10	163	48.4	1,783	0.7	49
85 and older	58	52.3	626	0.8	45	5	4.5	60	0.1	5	52	46.8	523	0.8	53
Female, Other E	Eligibles														
All Ages	6,654	54.0	69,864	0.8	43	586	4.8	6,305	0.2	65	5,816	47.2	60,924	0.8	52
64 or younger	69	26.1	522	0.7	40	59	22.3	623	1.0	500	92	34.8	757	0.7	48
65-74	1,776	68.7	19,461	0.9	48	106	4.1	1,170	0.2	59	1,474	57.0	16,225	0.8	56
75-84	2,161	55.4	22,798	0.8	43	157	4.0	1,756	0.1	6	1,889	48.4	19,858	0.8	52
85 and older	2,648	47.6	27,083	0.8	38	264	4.7	2,756	0.1	7	2,361	42.4	24,084	0.7	50
Male															
All Males	21,533	57.4	232,789	0.8	46	4,594	12.3	50,552	0.8	332	19,598	52.3	208,392	0.8	55
Male, Disabled															
All Ages	17,883	58.7	194,892	0.8	47	4,147	13.6	45,537	0.9	349	16,267	53.4	174,143	0.8	55
64 or younger	17,401	59.5	189,770	0.8	47	4,089	14.0	44,991	0.9	351	15,730	53.8	168,495	0.8	55
65-74	372	38.5	3,923	0.9	49	50	5.2	450	0.6	242	421	43.6	4,396	0.7	52
75-84	83	45.1	896	0.6	35	4	2.2	48	0.2	42	78	42.4	840	0.7	48
85 and older	27	47.4	303	1.1	59	4	7.0	48	0.1	8	38	66.7	412	0.7	35
Male, Other Elig	jibles														
All Ages	3,650	52.0	37,897	0.8	43	447	6.4	5,015	0.5	179	3,330	47.5	34,246	0.8	52
64 or younger	79	22.4	676	0.7	38	162	46.0	1,860			124	35.2	1,154	0.9	68
65-74	1,026	55.4	10,963	0.8	45	66	3.6	717			953	51.4	10,123		5
75-84	1,339	54.2	14,099			98	4.0	1,121			1,234	49.9	12,804		
85 and older	1,206	51.6	12,159			121	5.2	1,317		6	1,019	43.6	10,165		
Unknown	35	57.4	323	0.8	34	4	6.6	47	0.1	4	31	50.8	238	0.6	48

a. Table ND.10B includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 87,309 beneficiaries who were in nursing facilities for part of their enrollment and their 832,213 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each

group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10C

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY

AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGEa, b, c, d NONDUAL BENEFICIARIES, UNITED STATES, 2005

	MIS	C PSYCHOTI NEURO	HERAPEUTIC LOGICAL	AND			ANTID	IABETIC				ANALGESI	CS - Narcotio	0	
Beneficiary Characteristics	Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months Among N	Mean Number of Rx		Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months Among			Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months	Mean Number of Rx	
All	10,876	13.8	116,620	0.8	\$151	35,377	45.0	384,116	0.9	\$45	39,588	50.4	412,546	0.9	\$36
Female															
All Females	6,326	15.4	68,276	0.8	172	20,425	49.8	224,039	0.9	46	22,104	53.9	234,471	0.8	3
Female, Disable	ed														
All Ages	3,236	11.3	36,143	0.8	233	15,381	53.6	169,982	1.0	48	17,054	59.4	183,756	0.9	39
64 or younger	2,968	11.0	33,223	0.8	243	14,355	53.3	158,832	1.0	48	16,396	60.8	177,168	0.9	39
65-74	174	13.2	1,902	0.8	116	798	60.6	8,707	0.9	43	511	38.8	5,062	0.8	3
75-84	68	20.2	719	0.8	113	182	54.0	1,997	0.8	37	109	32.3	1,157	0.6	24
85 and older	26	23.4	299	0.8	101	46	41.4	446	0.8	44	38	34.2	369	0.5	19
Female, Other E	Eligibles														
All Ages	3,090	25.1	32,133	0.8	103	5,044	41.0	54,057	0.9	39	5,050	41.0	50,715	0.6	23
64 or younger	7	2.7	63	0.4	42	53	20.1	402	0.8	50	92	34.8	706	0.5	28
65-74	527	20.4	5,892	0.8	110	1,785	69.1	19,776	0.9	43	1,296	50.1	13,630	0.7	29
75-84	1,098	28.1	11,322	0.8	104	1,793	45.9	19,065	0.9	38	1,606	41.1	16,413	0.6	22
85 and older	1,458	26.2	14,856	0.8	100	1,413	25.4	14,814	0.8	36	2,056	37.0	19,966	0.6	20
Male															
All Males	4,521	12.1	48,066	0.8	121	14,939	39.9	159,958	0.9	44	17,462	46.6	177,885	0.9	37
Male, Disabled															
All Ages	2,758	9.1	29,826	0.7	131	12,219	40.1	131,560	0.9	45	14,827	48.7	151,986	0.9	39
64 or younger	2,598	8.9	28,029	0.7	133	11,685	39.9	125,747	0.9	45	14,500	49.6	148,848	0.9	39
65-74	98	10.2	1,080	0.7	88	427	44.2	4,551	0.8	38	262	27.2	2,484	0.8	2
75-84	46	25.0	529	0.7	101	83	45.1	977	0.8	38	45	24.5	433	0.5	
85 and older	16	28.1	188	0.7	93	24	42.1	285	0.7	26	20	35.1	221	0.4	
Male, Other Elig	gibles														
All Ages	1,763	25.1	18,240	0.8	106	2,716	38.7	28,386	0.9	41	2,633	37.5	25,893	0.6	25
64 or younger	16	4.5	126	0.5	158	59	16.8	387	0.9	45	87	24.7	684	0.4	27
65-74	372	20.1	3,966	0.8	107	1,029	55.5	10,962	0.9	43	718	38.7	7,183	0.6	23
75-84	703	28.4	7,321	0.8	104	1,049	42.4	11,149	0.9	40	951	38.5	9,706	0.7	25
85 and older	672	28.7	6,827	0.8	105	579	24.8	5,888	0.8	40	877	37.5	8,320	0.6	2
Unknown	29	47.5	278	0.8	100	17	27.9	131	0.8	37	24	39.3	196	0.7	1.

Source: Data for this table are from the MAX 2005 file for the U.S., released by CMS in 03/2009. This table was produced on 05/01/2009.

a. Table ND.10C includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 87,309 beneficiaries who were in nursing facilities for part of their enrollment and their 832,213 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled one group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26 2007).

Веле Mo(s) = benefit month(s); BDE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$=\$ Medicaid reimbursement.

TABLE ND.10D

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND $AGE^{a, b, c, d}$

NONDUAL BENEFICIARIES, UNITED STATES, 2005

ANTIHYPERLIPIDEMIC HEMATOPOIETIC AGENTS

Beneficiary Characteristics	Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months Among	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents		Mean Number of Rx	Mean Rx \$	All-Year Nursing Facility Residents	Benefit Months Among All- Year Nursing Facility Residents
All	19,055	24.3	211,001	0.8	\$69	16,937	21.6	179,539	0.7	\$78	78,574	819,830
Female												
All Females	10,538	25.7	117,319	0.8	69	8,660	21.1	93,396	0.7	83	41,028	432,326
Female, Disable	d											
All Ages	8,007	27.9	90,210	0.8	71	6,287	21.9	68,467	0.7	89	28,712	309,326
64 or younger	7,570	28.1	85,294	0.8	71	5,899	21.9	64,373	0.7	91	26,947	290,724
65-74	335	25.4	3,721	0.8	71	293	22.2	3,064	0.6	66	1,317	13,789
75-84	92	27.3	1,086	0.7	62	74	22.0	799	0.5	59	337	3,676
85 and older	10	9.0	109	0.7	67	21	18.9	231	0.6	138	111	1,137
Female, Other E	ligibles											
All Ages	2,531	20.6	27,109	0.8	66	2,373	19.3	24,929	0.7	65	12,316	123,000
64 or younger	22	8.3	178	0.8	89	28	10.6	218	0.6	84	264	1,769
65-74	885	34.2	9,867	0.8	70	559	21.6	6,057	0.7	70	2,585	27,677
75-84	970	24.8	10,187	0.8	66	803	20.6	8,602	0.7	60	3,904	39,525
85 and older	654	11.8	6,877	0.8	58	983	17.7	10,052	0.7	66	5,563	54,029
Male												
All Males	8,505	22.7	93,575	0.8	68	8,267	22.1	86,059	0.7	74	37,485	387,046
Male, Disabled												
All Ages	7,092	23.3	78,742	0.8	68	6,773	22.2	70,848	0.7	77	30,469	318,684
64 or younger	6,838	23.4	75,983	0.8	68	6,499	22.2	67,998	0.7	78	29,263	306,069
65-74	207	21.5	2,235	0.8	65	207	21.5	2,119	0.7	64	965	10,020
75-84	41	22.3	461	0.8	68	48	26.1	517	0.5	38	184	2,005
85 and older	6	10.5	63	1.2	76	19	33.3	214	0.6	28	57	590
Male, Other Elig	ibles											
All Ages	1,411	20.1	14,827	0.8	67	1,493	21.3	15,208	0.7	58	7,016	68,362
64 or younger	42	11.9	373	0.6	53	32	9.1	297	0.6	51	352	2,844
65-74	493	26.6	5,309	0.8	67	407	22.0	4,281	0.7	58	1,853	19,232
75-84	574	23.2	6,115	0.8	68	562	22.7	5,781	0.7	57	2,472	24,409
85 and older	302	12.9	3,030	0.8	66	492	21.0	4,849	0.6	59	2,339	21,877
Unknown	14	23.0	113	0.8	68	11	18.0	87	0.5	5	61	458

a. Table ND.10D includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 87,309 beneficiaries who were in nursing facilities for part of their enrollment and their 832,213 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.11 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC^{a,b} UNITED STATES, 2005

Beneficiary Characteristics	Number of Beneficiaries with at Least One Part D Excluded Rx	Percentage of Beneficiaries with at Least One Part D Excluded Rx		Total Number Part D Excluded Rx	Part D Excluded Rx \$ per Beneficiary	Total Part D Excluded Rx \$	\$ per Part D Excluded Rx	Percentage of All	Total Number of Beneficiaries
AII	9,478,813	26.6	1.1	37,957,467	\$17	\$620,523,972	\$16	3.4	35,581,286
Age									
5 and younger	3,020,468	33.9	1.0	9,254,021	15	129,331,476	14	8.5	8,901,626
6-14	2,060,951	23.7	0.6	5,221,435	12	106,893,029	20	3.9	8,705,266
15-20	938,971	18.0	0.5	2,377,279	10	50,579,005	21	3.0	5,204,027
21-44	2,043,470	21.4	0.9	8,731,292	15	147,110,393	17	2.8	9,548,019
45-64	1,273,251	45.5	4.0	11,149,220	62	172,108,919	15	2.6	2,798,266
65-74	77,953	45.3	3.9	667,902	47	8,007,297	12	2.8	171,957
75-84	41,072	41.5	3.7	365,561	44	4,393,617	12	2.9	99,046
85 and older	16,597	31.1	3.3	174,348	38	2,004,620	11	3.4	53,390
Unknown	6,080	6.1	0.2	16,409	1	95,616	6	5.0	99,689
Basis of Eligibility	:								
Aged	113,758	40.2	3.5	987,244	41	11,585,095	12	2.9	282,768
Disabled	1,926,321	45.1	3.7	15,991,404	74	317,099,374	20	2.9	4,272,811
Adults	1,927,841	18.8	0.6	6,161,196	8	83,555,101	14	2.8	10,247,240
Children	5,501,323	26.5	0.7	14,774,790	10	207,687,918	14	5.2	20,748,123
Unknown	9,570	31.5	1.4	42,833	20	596,484	14	1.3	30,344
Gender									
Female	5,659,734	26.8	1.1	23,394,874	18	369,866,913	16	3.6	21,135,029
Male	3,812,937	26.5	1.0	14,547,277	17	250,523,197	17	3.1	14,361,882
Unknown	6,142	7.3	0.2	15,316	2	133,862	9	4.3	84,375
Race									
White	4,087,702	27.0	1.2	17,862,139	20	306,588,523	17	3.1	15,132,845
African American	2,040,975	23.8	0.8	7,062,499	13	109,557,825	16	2.8	8,576,247
Other/unknown	3,350,136	28.2	1.1	13,032,829	17	204,377,624	16	4.5	11,872,194
Use of Nursing Fac	cilities ^d								
Entire year	51,477	65.5	12.6	992,168	168	13,207,921	13	3.0	78,574
Part year	65,085	74.5	9.2	799,574	161	14,043,055	18	3.4	87,309
None	9,362,251	26.4	1.0	36,165,725	17	593,272,996	16	3.4	35,415,403
Maintenance Assis	tance Status								
Cash	3,669,991	32.6	1.8	19,815,275	31	352,250,820	18	3.1	11,269,218
Medically needy	479,447	29.6	1.3	2,064,977	18	28,957,956	14	3.2	1,622,261
Poverty related	3,425,142	26.5	0.7	9,317,244	10	134,487,479	14	5.0	12,919,918
Other/unknown	1,904,233	19.5	0.7	6,759,971	11	104,827,717	16	3.0	9,769,889

a. Table ND.11 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2005

b. The statute establishing the Medicare Part D prescription program that started in 2006 excluded several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care or adoptive services.

d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.12 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a,b} UNITED STATES, 2005

Beneficiary Maracteristics	Number Rx per Benefit Month	Rx \$ per Benefit Month	\$ per Rx	Barbiturate \$ per Benefit Month	Benzodiazepine \$ per Benefit Month	Number of Benefit Months
All	0.1	\$2	\$16	\$0	\$0	278,081,082
Age						
5 and younger	0.1	2	14	0	0	65,854,904
6-14	0.1	1	20	0	0	72,564,303
15-20	0.1	1	21	0	0	40,515,314
21-44	0.1	2	17	0	1	70,605,113
45-64	0.4	7	15	0	2	25,119,533
65-74	0.4	5	12	0	1	1,596,746
75-84	0.4	5	12	0	1	923,575
85 and older	0.4	4	11	0	1	450,300
Unknown	0.0	0	6	0	0	451,294
Basis of Eligibility ^c						
Aged	0.4	5	12	0	1	2,556,582
Disabled	0.4	7	20	0	2	43,541,127
Adults	0.1	1	14	0	0	71,433,999
Children	0.1	1	14	0	0	160,289,855
Unknown	0.2	2	14	0	1	259,519
Gender						
Female	0.1	2	16	0	1	164,239,806
Male	0.1	2	17	0	0	113,330,412
Unknown	0.0	0	9	0	0	510,864
Race						
White	0.1	3	17	0	1	121,678,990
African American	0.1	2	16	0	0	70,605,862
Other/unknown	0.2	2	16	0	0	85,796,230
Use of Nursing Facil	ities ^d					
Entire year	1.2	16	13	0	5	819,830
Part year	1.0	17	18	0	4	832,213
None	0.1	2	16	0	0	276,429,039
Maintenance Assista	ince Status					
Cash	0.2	4	18	0	1	93,243,016
Medically needy	0.2	3	14	0	1	11,562,325
Poverty related	0.1	1	14	0	0	99,715,594
Other/unknown	0.1	1	16	0	0	73,560,147

a. Table ND.12 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2005.

b. The statute establishing the Medicare Part D prescription program that started in 2006 excluded several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include they barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services.

d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

TABLE ND.13

USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS^{a,b,c}

UNITED STATES, 2005

Brug Category

			D 00 0 7				
All	12,171,068	\$51	\$620,523,972	100.0	37,957,467	\$16	100.0
Anorexia or weight loss/gain	1,096	197	215,833	0.0	3,227	67	0.0
Fertility drugs	385	183	70,528	0.0	809	87	0.0
Drugs for cosmetic purposes	7,643	20	156,267	0.0	11,422	14	0.0
Cough and cold medications	4,107,808	37	151,893,225	24.5	7,687,014	20	20.3
Vitamins and minerals	782,263	60	46,664,234	7.5	2,663,446	18	7.0
Non-prescription drugs	5,670,852	40	228,749,919	36.9	19,126,744	12	50.4
Barbiturates	65,210	63	4,112,558	0.7	521,895	8	1.4
Benzodiazepines	1,277,142	103	130,920,306	21.1	7,228,348	18	19.0
Other Part D Excl Rx Drugs	258,669	223	57,741,102	9.3	714,562	81	1.9

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.13 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2005. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2005. A beneficiary who used drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table ND11.

b. Includes OTC drugs as well as prescription drugs.

c. The statute establishing the Medicare Part D prescription program that started in 2006 excluded several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription strains and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

APPENDIX TABLE A.1 $\textbf{CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY^{\textbf{a}, b}$ NONDUAL BENEFICIARIES, UNITED STATES, 2005

			Number of B	eneficiaries					Number of Be	enefit Months		
Beneficiary Characteristics	All	Aged	Blind/ Disabled	Adults	Children	Other/ Unknown	All	Aged	Blind/ Disabled	Adults	Children	Other/ Unknown
All	47,759,150	320,064	5,140,317	13,142,878	29,124,335	31,556	446,812,606	3,012,744	55,197,096	110,716,145	277,613,844	272,777
Age												
5 and younger	12,038,050	32	254,140	991	11,782,883	4	110,878,345	173	2,697,233	5,239	108,175,672	28
6-14	12,550,572	37	708,602	2,119	11,839,812	2	126,474,022	235	8,004,422	13,801	118,455,553	11
15-20	7,007,516	41	519,622	1,188,573	5,298,503	777	65,033,204	265	5,737,039	9,426,731	49,863,739	5,430
21-44	12,090,281	219	1,532,835	10,435,879	109,123	12,225	105,135,851	1,467	16,444,952	87,955,400	637,371	96,661
45-64	3,601,221	1,335	2,079,823	1,500,574	1,136	18,353	35,259,922	11,275	21,845,507	13,228,658	5,559	168,923
65-74	200,682	159,748	37,136	3,582	23	193	1,947,723	1,539,797	381,278	24,839	100	1,709
75-84	110,806	103,893	6,598	301	13	1	1,065,381	992,075	71,179	2,046	69	12
85 and older	56,403	54,618	1,545	209	31	0	483,608	466,799	15,386	1,178	245	C
Unknown	103,619	141	16	10,650	92,811	1	534,550	658	100	58,253	475,536	3
Gender												
Female	27,896,394	205,703	2,584,537	10,542,537	14,532,084	31,533	259,042,539	1,943,861	28,088,281	90,085,436	138,652,357	272,604
Male	19,773,857	114,115	2,555,545	2,595,806	14,508,369	22	187,206,170	1,066,841	27,106,904	20,616,663	138,415,592	170
Unknown	88,899	246	235	4,535	83,882	1	563,897	2,042	1,911	14,046	545,895	3
Race												
White	19,289,224	99,189	2,372,114	5,418,927	11,382,324	16,670	179,553,028	888,553	25,159,037	45,220,001	108,147,302	138,135
African American	11,834,123	50,300	1,416,597	2,876,500	7,486,364	4,362	116,521,336	475,028	15,361,148	25,637,728	75,009,317	38,115
Other/unknown	16,635,803	170,575	1,351,606	4,847,451	10,255,647	10,524	150,738,242	1,649,163	14,676,911	39,858,416	94,457,225	96,527
Use of Nursing Facilities ^c												
Entire year	79,258	18,959	59,676	359	259	5	828,073	189,376	634,142	2,416	2,110	29
Part year	89,255	11,673	70,782	4,839	1,884	77	898,027	109,357	724,648	45,831	17,424	767
None	47,590,637	289,432	5,009,859	13,137,680	29,122,192	31,474	445,086,506	2,714,011	53,838,306	110,667,898	277,594,310	271,981
Maintenance Assistance Statu	ıs											
Cash	17,045,442	95,417	4,314,706	4,299,011	8,336,308	0	171,825,874	999,459	47,697,341	38,841,758	84,287,316	C
Medically needy	2,114,396	102,254	201,447	906,387	904,308	0	18,286,254	957,764	1,710,508	7,548,839	8,069,143	C
Poverty related	16,160,168	45,228	222,966	1,386,730	14,473,688	31,556	148,457,261	401,120	2,028,204	8,628,911	137,126,249	272,777
Other/unknown	12,439,144	77,165	401,198	6,550,750	5,410,031	0	108,243,217	654,401	3,761,043	55,696,637	48,131,136	C
Full dual, all year	0	0	0	0	0	0	0	0	0	0	0	C
Non-dual, all year	47,759,150	320,064	5,140,317	13,142,878	29,124,335	31,556	446,812,606	3,012,744	55,197,096	110,716,145	277,613,844	272,777
Managed Care (MC) Status												
Fee-for-service (FFS) all year	26,266,896	263,783	3,843,255	7,692,894	14,436,941	30,023	232,223,818	2,445,490	40,636,971	59,417,813	129,465,741	257,803
FFS part year, with Rx claims	3,098,812	8,008	202,613	992,740	1,895,250	201	31,004,709	82,570	2,201,407	9,359,105	19,359,608	2,019
FFS part year, no Rx claims	4,282,801	6,428	97,352	1,056,402	3,122,527	92	39,157,249	56,883	955,772	9,045,262	29,098,545	787
MC all year, with Rx claims	2,370,494	6,959	297,633	612,116	1,453,745	41	25,966,006	79,305	3,481,876	6,486,679	15,917,737	409
MC all year, no Rx claims	11,737,275	34,886	699,454	2,788,612	8,213,138	1,185	118,448,982	348,496	7,921,022	26,407,162	83,760,633	11,669

a. Table A.1 includes the beneficiaries represented by Cell J of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

C. Please refer to footnote of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract;

MC = managed care; Rx = pharmacy benefit.

APPENDIX TABLE A.2

MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS^a NONDUAL BENEFICIARIES, UNITED STATES, 2005

	Beneficia Benefit Month					
	Tab		Included in Ce	ll K of Table 1	Excluded from (Cell K of Table 1
	Number of Beneficiaries	Number of Benefit Months	Number of Beneficiaries	Number of Benefit Months	Number of Beneficiaries	Number of Benefit Months
All	47,759,150	446,812,606	35,581,286	278,081,082	437,717	168,731,524
Fee-for-service (FFS) all year	26,266,896	232,223,818	26,266,896	232,161,989	0	61,829
FFS part year, with Rx claims	3,098,812	31,004,709	3,098,805	12,675,539	7	18,329,170
FFS part year, with no Rx claims	4,282,801	39,157,249	4,282,772	12,150,128	29	27,007,121
Managed care (MC) all year, with Rx claims	2,370,494	25,966,006	1,932,813	21,093,426	437,681	4,872,580
MC all year, with no Rx claims	11,737,275	118,448,982	0	0	0	118,448,982
Unknown	2,872	11,842	0	0	0	11,842

Source: Data for this table are from the MAX 2005 file for the U.S., released by CMS in 03/2009. This table was produced on 05/01/2009.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

APPENDIX TABLE A.3 MANAGED CARE PENETRATION RATES, ALL STATES COMBINED AND BY STATE, BY BASIS OF ELIGIBILITY NONDUAL BENEFICIARIES, UNITED STATES, 2005^{a,b}

All Nonduals Aged/Disabled Adults/Children

	Number of Beneficiaries	Percentage of Beneficiaries Enrolled in MC all Year	Number of Beneficiaries	Beneficiaries Enrolled in MC all	Percentage of Beneficiaries Enrolled in MC all Year	Number of Beneficiaries	Number of Beneficiaries Enrolled in MC all Year	Percentage of Beneficiaries Enrolled in MC all Year
All States	47,759,150	29.5	5,460,381	1,038,932	19.0	42,267,213	13,067,611	30.9
Alabama	756,993	0.0	112,591	53	0.0	644,045	2	0.0
Alaska	119,692	0.0	9,126	0	0.0	110,408	0	0.0
Arizona	1,203,330	86.6	85,162	58,580	68.8	1,118,063	983,254	87.9
Arkansas	642,724	0.0	72,260	0	0.0	569,990	0	0.0
California	8,458,442	33.9	715,094	157,628	22.0	7,734,952	2,710,655	35.0
Colorado	467,100	8.5	51,825	9,550	18.4	415,071	30,027	7.2
Connecticut	430,889	70.8	32,278	10	0.0	398,409	304,882	76.5
Delaware	150,441	94.4	11,877	11,831	99.6	138,516	130,189	94.0
D.C.	144,766	62.2	25,002	2,826	11.3	119,764	87,252	72.9
Florida	2,377,755	25.0	316,677	78,010	24.6	2,060,847	515,899	25.0
Georgia	1,574,358	0.0	163,920	0	0.0	1,407,172	0	0.0
Hawaii	200,077	66.6	16,394	1,276	7.8	183,641	131,885	71.8
Idaho	201,907	0.0	20,135	0	0.0	181,772	0	0.0
Illinois	1,951,446	5.7	197,224	35	0.0	1,753,691	112,104	6.4
Indiana	854,964	31.6	81,561	7,039	8.6	773,189	263,151	34.0
Iowa	352,789	1.4	34,572	0	0.0	317,993	4,768	1.5
Kansas	294,578	14.3	34,273	5	0.0	260,159	42,205	16.2
Kentucky	710,159	21.9	140,001	23,504	16.8	569,730	132,285	23.2
Louisiana	979,374	0.0	134,150	0	0.0	844,315	0	0.0
Maine								
Maryland	731,554	60.0	91,121	58,628	64.3	640,029	380,607	59.5
Massachusetts	843,147	32.3	148,648	19,386	13.0	694,499	252,898	36.4
Michigan	1,485,647	47.5	180,334	110,445	61.2	1,304,143	594,874	45.6
Minnesota	613,240	39.1	58,902	2,406	4.1	553,896	237,661	42.9
Mississippi	606,010	0.0	97,609	0	0.0	508,227	0	0.0
Missouri	1,030,039	41.4	108,553	416	0.4	920,951	425,621	46.2
Montana	81,885	0.0	11,462	0	0.0	70,411	0	0.0
Nebraska	220,859	53.7	16,949	9,925	58.6	203,535	108,671	53.4
Nevada	224,699	32.8	22,225	0	0.0	202,294	73,728	36.4
New Hampshire	113,437	0.0	9,322	0	0.0	104,115	0	0.0
New Jersey	814,470	60.1	106,985	37,819	35.3	707,194	451,795	63.9
New Mexico	471,384	36.8	37,616	23,557	62.6	433,490	149,783	34.6
New York	3,733,067	51.5	470,061	94,287	20.1	3,262,152	1,828,393	56.0
North Carolina	1,267,243	0.6	160,718	351	0.2	1,106,525	7,167	0.6
North Dakota	59,444	1.0	4,726	0	0.0	54,718	612	1.1
Ohio	1,833,610	24.0	224,648	2,075	0.9	1,608,962	438,735	27.3

APPENDIX TABLE A.3 MANAGED CARE PENETRATION RATES, ALL STATES COMBINED AND BY STATE, BY BASIS OF ELIGIBILITY NONDUAL BENEFICIARIES, UNITED STATES, 2005^{a,b}

Aged/Disabled

Adults/Children

Percentage of Number of Percentage of Number of Percentage of Beneficiaries Beneficiaries Beneficiaries Beneficiaries Beneficiaries Number of Enrolled in MC all Enrolled in MC Number of Enrolled in MC Number of Enrolled in MC all Enrolled in Beneficiaries all Year Beneficiaries Year MC all Year Beneficiaries Year all Year Oklahoma 618,593 0.0 55,978 0 0.0 0 558,548 0.0 392,223 55.0 Oregon 24,732 43,364 57.0 348,519 191,174 54.9 Pennsylvania 1,621,601 61.0 335,757 217,788 771,957 60.1 64.9 1,284,524 Rhode Island 179,583 66.7 25,585 3,656 14.3 153,685 116,142 75.6 South Carolina 820,179 5.2 97.547 4.304 4.4 722,208 37,984 5.3 South Dakota 109,338 0.0 8,685 0.0 100,594 0 0.0 Tennessee 1,281,414 0.0 178,623 0 0 0.0 0.0 1,100,861 Texas 3,425,751 17.1 328,498 41,284 12.6 3,096,694 544,219 17.6 Utah 249,807 0.0 19.464 0.0 230.030 0 0.0 Vermont 126,454 0.0 0 9,395 0 0.0 116,959 0.0 Virginia 709,637 39.3 86,967 34,364 39.5 622,285 244,824 39.3 Washington 1,030,787 40.0 109,707 2,115 1.9 920,702 409,900 44.5 West Virginia 319,073 20.2 72,293 825 63,487 25.7 1.1 246,583 802,504 36.0 Wisconsin 40.0 79.377 222 0.3 722,758 288,821

Source: Data for this table are from the MAX 2005 file for the U.S., released by CMS in 03/2009. This table was produced on 05/01/2009.

70,687

All Nonduals

Wyoming

0.0

5,140

Appendix Table A.3

0

0.0

65,395

0

0.0

a. Appendix Table A.3 was derived from data contained in Appendix Table A.1 for each state.

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

CMS = Centers for Medicare & Medicaid Services; D.C. = District of Columbia; MAX = Medicaid Analytic Extract; MC = managed care.